全文获取类型
收费全文 | 3519篇 |
免费 | 278篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 52篇 |
儿科学 | 66篇 |
妇产科学 | 41篇 |
基础医学 | 508篇 |
口腔科学 | 52篇 |
临床医学 | 352篇 |
内科学 | 756篇 |
皮肤病学 | 55篇 |
神经病学 | 422篇 |
特种医学 | 92篇 |
外科学 | 445篇 |
综合类 | 59篇 |
一般理论 | 2篇 |
预防医学 | 355篇 |
眼科学 | 45篇 |
药学 | 347篇 |
中国医学 | 4篇 |
肿瘤学 | 153篇 |
出版年
2022年 | 14篇 |
2021年 | 36篇 |
2020年 | 30篇 |
2019年 | 48篇 |
2018年 | 35篇 |
2017年 | 38篇 |
2016年 | 58篇 |
2015年 | 61篇 |
2014年 | 85篇 |
2013年 | 131篇 |
2012年 | 205篇 |
2011年 | 225篇 |
2010年 | 128篇 |
2009年 | 122篇 |
2008年 | 232篇 |
2007年 | 252篇 |
2006年 | 262篇 |
2005年 | 215篇 |
2004年 | 227篇 |
2003年 | 215篇 |
2002年 | 216篇 |
2001年 | 62篇 |
2000年 | 49篇 |
1999年 | 60篇 |
1998年 | 60篇 |
1997年 | 43篇 |
1996年 | 42篇 |
1995年 | 53篇 |
1994年 | 29篇 |
1993年 | 22篇 |
1992年 | 30篇 |
1991年 | 34篇 |
1990年 | 39篇 |
1989年 | 34篇 |
1988年 | 38篇 |
1987年 | 29篇 |
1986年 | 28篇 |
1985年 | 29篇 |
1984年 | 26篇 |
1983年 | 27篇 |
1982年 | 24篇 |
1981年 | 27篇 |
1980年 | 19篇 |
1979年 | 21篇 |
1978年 | 14篇 |
1977年 | 14篇 |
1976年 | 9篇 |
1974年 | 9篇 |
1972年 | 13篇 |
1966年 | 12篇 |
排序方式: 共有3806条查询结果,搜索用时 187 毫秒
51.
52.
Dean PG van Heerden JA Farley DR Thompson GB Grant CS Harmsen WS Ilstrup DM 《World journal of surgery》2000,24(11):1437-1441
Multiple endocrine neoplasia type I (MEN-I) is an autosomal dominant disorder characterized by endocrinopathies involving
the anterior pituitary gland, parathyroid glands, and pancreas. The long-term prognosis for patients affected with this disorder
is uncertain. To better characterize this prognosis, we performed a retrospective review of all patients with MEN-I treated
at a single institution during the period 1951–1997. A group of 233 patients served as the study population. Their records
were analyzed for confirmation of diagnosis, treatments received, long-term survival, and cause of death. Altogether, 108
eight male patients (46%) and 125 female patients (54%) were identified. At the conclusion of the study, 164 (70%) were alive
and 69 (30%) were deceased, with a median follow-up for patients alive at last contact of 13.4 years (range < 1 month to 54.3
years). The cause of death was reliably obtained in 60 patients. Of these patients, 17 (28%) died of causes related to MEN-I,
most commonly metastatic islet cell tumors (10 patients). The remaining patients died of causes unrelated to MEN-I, most commonly
coronary artery disease and nonendocrine malignancies (14% each). The overall 20-year survival of MEN-I patients was 64% (95%
CI was 56–72%), and that of an age- and gender-matched upper Midwest population was 81% (p < 0.001). Patients with MEN-I appear to be at increased risk of premature death. Earlier diagnosis and treatment of potentially
malignant pancreatic islet cell neoplasms may result in a decrease of this premature mortality. 相似文献
53.
目的 建立一种快速有效的分析方法 ,达到鉴定淫羊藿及人参复方产品中黄酮苷类及人参皂苷类成分 ,并测定各成分含量的目的 ,最终控制复方中淫羊藿及人参的比例。方法 通过反相液相色谱 ,对包括药典所收载的淫羊藿药材及其产品进行分析。淫羊藿中的主要黄酮苷类成分 ,以淫羊藿定A、淫羊藿定B、淫羊藿定C、淫羊藿苷为对照品 ;对主要的人参皂苷类成分 ,以人参皂苷Rg1 、Re、Rf、Rb1 、Rb2 、Rd为对照品。结果 在同一色谱条件下 ,对主要黄酮苷类及人参皂苷类成分均可同时测定且分离良好。结论 该方法适用于淫羊藿、人参及其复方产品中淫羊藿黄酮苷类、人参皂苷类成分的定性、定量分析 相似文献
54.
Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells. 总被引:1,自引:0,他引:1
55.
Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. 总被引:3,自引:0,他引:3
Shaoliang Chen Like Yu Changying Jiang Yan Zhao Da Sun Shenyu Li Guoqing Liao Yangchun Chen Qing Fu Qun Tao Dan Ye Peisheng Hu Leslie A Khawli Clive R Taylor Alan L Epstein Dian Wen Ju 《Journal of clinical oncology》2005,23(7):1538-1547
PURPOSE: Tumor necrosis treatment (TNT) uses degenerating tumor cells and necrotic regions of tumors as targets for radioimmunotherapy. Previous studies in animal tumor models and clinical trials have demonstrated that when linked to the therapeutic radionuclide iodine-131, recombinant chimeric TNT antibody ((131)I-chTNT) can deliver therapeutic doses to tumors regardless of the location or type of malignancy. Therapeutic efficacy and toxicity of (131)I-chTNT in advanced lung cancer patients were studied in this pivotal registration trial. PATIENTS AND METHODS: Patients with advanced lung cancer were treated with systemic or intratumoral injection of (131)I-chTNT in eight oncology centers in China. The objective response rate (ORR) was assessed as the primary end point. RESULTS: All 107 patients who were entered onto the study and completed therapy had experienced treatment failure after prior radiotherapy or chemotherapy a mean of three times. The results showed an ORR of 34.6% (complete response, 3.7%; partial response, 30.8%; no change, 55.1%; and progressive disease, 10.3%) in all patients and 33% in 97 non-small-cell lung cancer patients. A biodistribution study demonstrated excellent localization of the radioactivity in tumors in both systemically and intratumorally injected patients. The most obvious adverse side effect was mild and reversible bone marrow suppression. CONCLUSION: Radioimmunotherapy with (131)I-chTNT was well tolerated and can be used systemically or locally to treat refractory tumors of the lung. 相似文献
56.
Mitch Dowsett Steve R Ebbs J Michael Dixon Anthony Skene Clive Griffith Irene Boeddinghaus Janine Salter Simone Detre Margaret Hills Susan Ashley Stephen Francis Geraldine Walsh Ian E Smith 《Journal of clinical oncology》2005,23(11):2477-2492
PURPOSE: To investigate the relationships between biomarker changes in breast cancer during neoadjuvant (preoperative) endocrine therapy. PATIENTS AND METHODS: The IMPACT trial compared the preoperative use of tamoxifen with anastrozole alone or in combination in postmenopausal women (n = 330) with primary breast cancer. Biomarkers were measured in tumor biopsy specimens taken at baseline, and after 2 and 12 weeks of treatment. RESULTS: 52 (93%) of 56, 46 (85%) of 54, and 37 (84%) of 44 patients in the anastrozole, tamoxifen, and combination groups, respectively. There was a significantly greater suppression of Ki67 in the anastrozole-treated group than in the tamoxifen- or combination-treated groups, which is parallel to the greater efficacy seen for anastrozole over these two treatments in the Arimidex, Tamoxifen, Alone or in Combination adjuvant trial. A positive relationship was noted between estrogen-receptor level and Ki67 suppression in all patients. Ki67 was reduced to a greater extent in progesterone receptor-positive tumors compared with progesterone receptor-negative tumors. HER-2-negative tumors tended to show a greater reduction in Ki67 compared with HER-2-positive tumors, but the difference was only significant in the tamoxifen group after 2 weeks, and in the anastrozole group after 12 weeks. CONCLUSION: These results confirm the value of Ki67 as a molecular marker, and provide information regarding the relationships between treatment-induced changes in Ki67 and other important biomarkers. Studies such as this should help integrate agents targeted at growth factor signaling with endocrine agents in breast cancer. 相似文献
57.
Maria L. Napier Dash Durga Clive J. Wolsley Sarah Chamney Sharon Alexander Rosie Brennan 《Ophthalmic genetics》2015,36(3):239-243
Background: To determine the role of rhodopsin (RHO) gene mutations in patients with sector retinitis pigmentosa (RP) from Northern Ireland.Design: A case series of sector RP in a tertiary ocular genetics clinic.Participants: Four patients with sector RP were recruited from the Royal Victoria Hospital (Belfast, Northern Ireland) and Altnagelvin Hospital (Londonderry, Northern Ireland) following informed consent.Methods: The diagnosis of sector RP was based on clinical examination, International Society for Clinical Electrophysiology of Vision (ISCEV) standard electrophysiology, and visual field analysis. DNA was extracted from peripheral blood leucocytes and the coding regions and adjacent flanking intronic sequences of the RHO gene were polymerase chain reaction (PCR) amplified and cycle sequenced.Main Outcome Measure: Rhodopsin mutational status.Results: A heterozygous missense mutation in RHO (c.173C?>?T) resulting in a non-conservative substitution of threonine to methionine (p. Thr58Met) was identified in one patient and was absent from 360 control individuals. This non-conservative substitution (p.Thr58Met) replaces a highly evolutionary conserved polar hydrophilic threonine residue with a non-polar hydrophobic methionine residue at position 58 near the cytoplasmic border of helix A of RHO.Conclusions: The study identified a RHO gene mutation (p.Thr58Met) not previously reported in RP in a patient with sector RP. These findings outline the phenotypic variability associated with RHO mutations. It has been proposed that the regional effects of RHO mutations are likely to result from interplay between mutant alleles and other genetic, epigenetic and environmental factors. 相似文献
58.
60.